By David Cassak
Given the phenomenal success of, first, bare metal coronary stents and, more recently, drug-eluting stents, it's sometimes difficult to imagine...
Biotronik's Disappearing Act
Listen to this article
Any concerns about coronary stents and their safety have, obviously, long been put to rest. But one concern still lingers in the minds of some: why use a permanent device to do a temporary job? Phrased differently, how much better would it be to have a stent that, upon completing the remodeling job to keep the arteries open, simply disappeared? That's the promise of bioabsorbable stents. And one company, Berlin-based Biotronik GMBH & Co., hopes to capitalize on that promise.
Candid conversations with C-suite leaders.
More from In Vivo Archive
In Partnership with Cerba Research
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Digital clinical trials, a trend sparked by the COVID-19 pandemic that has held the biopharma industry’s interest, are changing the way patients interact with research and improving access, says Medable’s CEO.
• By
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
• By
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
More from In Vivo
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.